Which has preferable earnings & valuation, LMRI or LFMD?

LifeMD has lower revenue, but higher earnings than Lumexa Imaging. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lumexa Imaging $267.73M 2.80 N/A N/A N/A LifeMD $194.05M 1.11 $14.35M $0.05 88.90

Is LMRI or LFMD more profitable?

LifeMD has a net margin of 2.37% compared to Lumexa Imaging's net margin of 0.00%. Lumexa Imaging's return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets Lumexa Imaging N/A N/A N/A LifeMD 2.37% -150.88% -22.59%

Is LFMD or CSTL more profitable?

LifeMD has a net margin of 2.37% compared to Castle Biosciences' net margin of -3.78%. Castle Biosciences' return on equity of -2.77% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Castle Biosciences -3.78% -2.77% -2.30%

Is LFMD or FLGT more profitable?

LifeMD has a net margin of 2.37% compared to Fulgent Genetics' net margin of -23.04%. Fulgent Genetics' return on equity of -3.24% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Fulgent Genetics -23.04% -3.24% -2.97%

Do analysts recommend MCTA or LFMD?

LifeMD has a consensus price target of $9.14, indicating a potential upside of 105.69%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Charming Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Charming Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 LifeMD 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has better valuation & earnings, MCTA or LFMD?

LifeMD has higher revenue and earnings than Charming Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Charming Medical N/A N/A N/A N/A N/A LifeMD $194.05M 1.11 $14.35M $0.05 88.90

LifeMD (LFMD) Competitors

$4.44 -0.15 (-3.16%)

As of 02:13 PM Eastern

Compare

LFMD vs. LMRI, CSTL, FLGT, MCTA, and TOI

Should you buy LifeMD stock or one of its competitors? MarketBeat compares LifeMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LifeMD include Lumexa Imaging (LMRI), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Charming Medical (MCTA), and Oncology Institute (TOI). These companies are all part of the "healthcare" industry.

How does LifeMD compare to Lumexa Imaging?

Lumexa Imaging (NASDAQ:LMRI) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Lumexa Imaging currently has a consensus target price of $16.00, indicating a potential upside of 105.10%. LifeMD has a consensus target price of $9.14, indicating a potential upside of 105.69%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than Lumexa Imaging.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, LifeMD had 8 more articles in the media than Lumexa Imaging. MarketBeat recorded 11 mentions for LifeMD and 3 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.95 beat LifeMD's score of 0.43 indicating that Lumexa Imaging is being referred to more favorably in the media.

Company	Overall Sentiment
Lumexa Imaging	Positive
LifeMD	Neutral

LifeMD has lower revenue, but higher earnings than Lumexa Imaging.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lumexa Imaging	$267.73M	2.80	N/A	N/A	N/A
LifeMD	$194.05M	1.11	$14.35M	$0.05	88.90

LifeMD has a net margin of 2.37% compared to Lumexa Imaging's net margin of 0.00%. Lumexa Imaging's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lumexa Imaging	N/A	N/A	N/A
LifeMD	2.37%	-150.88%	-22.59%

35.5% of LifeMD shares are owned by institutional investors. 0.7% of Lumexa Imaging shares are owned by insiders. Comparatively, 18.4% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

LifeMD beats Lumexa Imaging on 7 of the 13 factors compared between the two stocks.

How does LifeMD compare to Castle Biosciences?

LifeMD (NASDAQ:LFMD) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 18.4% of LifeMD shares are owned by company insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LifeMD has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.11	$14.35M	$0.05	88.90
Castle Biosciences	$344.23M	1.87	-$24.16M	-$0.44	N/A

In the previous week, LifeMD had 3 more articles in the media than Castle Biosciences. MarketBeat recorded 11 mentions for LifeMD and 8 mentions for Castle Biosciences. LifeMD's average media sentiment score of 0.43 beat Castle Biosciences' score of -0.75 indicating that LifeMD is being referred to more favorably in the media.

Company	Overall Sentiment
LifeMD	Neutral
Castle Biosciences	Negative

LifeMD has a net margin of 2.37% compared to Castle Biosciences' net margin of -3.78%. Castle Biosciences' return on equity of -2.77% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Castle Biosciences	-3.78%	-2.77%	-2.30%

LifeMD presently has a consensus target price of $9.14, suggesting a potential upside of 105.69%. Castle Biosciences has a consensus target price of $42.83, suggesting a potential upside of 101.90%. Given LifeMD's stronger consensus rating and higher possible upside, analysts plainly believe LifeMD is more favorable than Castle Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

LifeMD has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Summary

LifeMD beats Castle Biosciences on 11 of the 16 factors compared between the two stocks.

How does LifeMD compare to Fulgent Genetics?

LifeMD (NASDAQ:LFMD) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, LifeMD had 4 more articles in the media than Fulgent Genetics. MarketBeat recorded 11 mentions for LifeMD and 7 mentions for Fulgent Genetics. LifeMD's average media sentiment score of 0.43 beat Fulgent Genetics' score of 0.21 indicating that LifeMD is being referred to more favorably in the media.

Company	Overall Sentiment
LifeMD	Neutral
Fulgent Genetics	Neutral

LifeMD has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

LifeMD has a net margin of 2.37% compared to Fulgent Genetics' net margin of -23.04%. Fulgent Genetics' return on equity of -3.24% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Fulgent Genetics	-23.04%	-3.24%	-2.97%

LifeMD has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.11	$14.35M	$0.05	88.90
Fulgent Genetics	$322.67M	1.63	-$60.51M	-$2.39	N/A

35.5% of LifeMD shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 18.4% of LifeMD shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LifeMD presently has a consensus target price of $9.14, suggesting a potential upside of 105.69%. Fulgent Genetics has a consensus target price of $27.00, suggesting a potential upside of 45.43%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

LifeMD beats Fulgent Genetics on 10 of the 16 factors compared between the two stocks.

How does LifeMD compare to Charming Medical?

Charming Medical (NASDAQ:MCTA) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

35.5% of LifeMD shares are owned by institutional investors. 18.4% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LifeMD has a consensus price target of $9.14, indicating a potential upside of 105.69%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Charming Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charming Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, LifeMD had 7 more articles in the media than Charming Medical. MarketBeat recorded 11 mentions for LifeMD and 4 mentions for Charming Medical. Charming Medical's average media sentiment score of 0.78 beat LifeMD's score of 0.43 indicating that Charming Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Charming Medical	Positive
LifeMD	Neutral

LifeMD has a net margin of 2.37% compared to Charming Medical's net margin of 0.00%. Charming Medical's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charming Medical	N/A	N/A	N/A
LifeMD	2.37%	-150.88%	-22.59%

LifeMD has higher revenue and earnings than Charming Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charming Medical	N/A	N/A	N/A	N/A	N/A
LifeMD	$194.05M	1.11	$14.35M	$0.05	88.90

Summary

LifeMD beats Charming Medical on 8 of the 11 factors compared between the two stocks.

How does LifeMD compare to Oncology Institute?

LifeMD (NASDAQ:LFMD) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

LifeMD has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.11	$14.35M	$0.05	88.90
Oncology Institute	$502.73M	0.89	-$60.61M	-$0.37	N/A

LifeMD presently has a consensus target price of $9.14, indicating a potential upside of 105.69%. Oncology Institute has a consensus target price of $7.00, indicating a potential upside of 54.02%. Given LifeMD's stronger consensus rating and higher probable upside, analysts clearly believe LifeMD is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, LifeMD had 7 more articles in the media than Oncology Institute. MarketBeat recorded 11 mentions for LifeMD and 4 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.42 beat LifeMD's score of 0.43 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Overall Sentiment
LifeMD	Neutral
Oncology Institute	Positive

LifeMD has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

35.5% of LifeMD shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 18.4% of LifeMD shares are held by insiders. Comparatively, 8.5% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LifeMD has a net margin of 2.37% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Oncology Institute	-7.42%	N/A	-24.68%

Summary

LifeMD beats Oncology Institute on 12 of the 16 factors compared between the two stocks.

Get LifeMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFMD vs. The Competition

Export

Metric	LifeMD	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$215.20M	$8.55B	$6.42B	$12.58B
Dividend Yield	N/A	2.99%	2.75%	5.26%
P/E Ratio	89.02	21.73	21.29	26.31
Price / Sales	1.11	20.00	562.18	114.16
Price / Cash	N/A	88.04	43.49	56.90
Price / Book	14.34	5.98	10.61	7.34
Net Income	$14.35M	$183.47M	$3.56B	$336.95M
7 Day Performance	6.09%	3.49%	3.36%	3.65%
1 Month Performance	0.34%	13.25%	6.63%	7.39%
1 Year Performance	-61.31%	6.61%	36.99%	37.74%

LifeMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFMD LifeMD	4.354 of 5 stars	$4.45 -3.2%	$9.14 +105.7%	-60.0%	$215.20M	$194.05M	89.02	230	Trending News Analyst Forecast Analyst Revision
LMRI Lumexa Imaging	4.2164 of 5 stars	$8.00 flat	$16.00 +100.0%	N/A	$768.65M	$267.73M	N/A	4,335	Positive News Gap Up
CSTL Castle Biosciences	3.8085 of 5 stars	$20.15 flat	$45.33 +125.0%	+36.2%	$611.15M	$344.23M	N/A	540	Analyst Downgrade
FLGT Fulgent Genetics	2.949 of 5 stars	$17.11 flat	$27.00 +57.8%	-11.2%	$508.97M	$322.67M	N/A	1,315
MCTA Charming Medical	N/A	$29.36 flat	N/A	N/A	$497.21M	N/A	N/A	49	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFMD) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeMD (LFMD) Competitors

LFMD vs. LMRI, CSTL, FLGT, MCTA, and TOI

How does LifeMD compare to Lumexa Imaging?

Summary

How does LifeMD compare to Castle Biosciences?

Summary

How does LifeMD compare to Fulgent Genetics?

Summary

How does LifeMD compare to Charming Medical?

Summary

How does LifeMD compare to Oncology Institute?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LifeMD (LFMD) Competitors

LFMD vs. LMRI, CSTL, FLGT, MCTA, and TOI

How does LifeMD compare to Lumexa Imaging?

Do analysts prefer LMRI or LFMD?

Does the media favor LMRI or LFMD?

Which has preferable earnings & valuation, LMRI or LFMD?

Is LMRI or LFMD more profitable?

Do institutionals and insiders believe in LMRI or LFMD?

Summary

How does LifeMD compare to Castle Biosciences?

Do insiders and institutionals have more ownership in LFMD or CSTL?

Which has higher earnings & valuation, LFMD or CSTL?

Does the media refer more to LFMD or CSTL?

Is LFMD or CSTL more profitable?

Do analysts rate LFMD or CSTL?

Which has more volatility & risk, LFMD or CSTL?

Summary

How does LifeMD compare to Fulgent Genetics?

Does the media refer more to LFMD or FLGT?

Which has more volatility & risk, LFMD or FLGT?

Is LFMD or FLGT more profitable?

Which has preferable valuation & earnings, LFMD or FLGT?

Do institutionals and insiders believe in LFMD or FLGT?

Do analysts prefer LFMD or FLGT?

Summary

How does LifeMD compare to Charming Medical?

Do insiders and institutionals believe in MCTA or LFMD?

Do analysts recommend MCTA or LFMD?

Does the media prefer MCTA or LFMD?

Is MCTA or LFMD more profitable?

Which has better valuation & earnings, MCTA or LFMD?

Summary

How does LifeMD compare to Oncology Institute?

Which has stronger valuation and earnings, LFMD or TOI?

Do analysts recommend LFMD or TOI?

Does the media favor LFMD or TOI?

Which has more risk and volatility, LFMD or TOI?

Do institutionals & insiders have more ownership in LFMD or TOI?

Is LFMD or TOI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools